Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials

Leow, Jeffrey J.; Martin‐Doyle, William; Rajagopal, Padma Sheila; Patel, Chirayu G.; Anderson, Erin M.; Rothman, Andrew; Côté, Richard J.; Ürün, Yüksel; Chang, Steven L.; Choueiri, Toni K.; Bellmunt, Joaquim

doi:10.1016/j.eururo.2013.08.033

Cited by 366 publications

(253 citation statements)

References 31 publications

Supporting

Mentioning

231

Contrasting

Unclassified

Order By: Relevance

“…Studies have shown that adjuvant chemotherapy may delay recurrences and improve OS, [27][28][29] but no randomized comparisons of adequate sample size have definitively shown a survival benefit, in large part due to poor accrual. 30 Clinical trials of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP); MVAC; and methotrexate, vinblastine, epirubicin, and cisplatin (MVEC) regimens have each suggested a survival advantage.…”

Section: Adjuvant Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Spiess¹,

Agarwal²,

Bangs³

et al. 2017

J Natl Compr Canc Netw

225

173

View full text Add to dashboard Cite

OverviewAn estimated 79,030 new cases of urinary bladder cancer (60,490 men and 18,540 women) will be diagnosed in the United States in 2017 and approximately 16,870 deaths (12,240 men and 4630 women) will occur. Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Disclosures for the NCCN Bladder Cancer PanelAt the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.Individual disclosures for the NCCN Bladder Cancer Panel members can be found on page 1267 (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

Section: Adjuvant Chemotherapymentioning

confidence: 99%

“…• Ifosfamide, doxorubicin, and gemcitabine 16 • Gemcitabine and paclitaxel 15 • Gemcitabine and cisplatin 4 • DDMVAC • Cisplatin a and paclitaxel 28,29 • 5-FU and mitomycin 30 • Cisplatin a alone 31…”

mentioning

confidence: 99%

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Spiess¹,

Agarwal²,

Bangs³

et al. 2017

J Natl Compr Canc Netw

225

173

View full text Add to dashboard Cite

show abstract

“…For muscle-invasive BCa, radical cystectomy is recommended, accompanied by neo-adjuvant chemotherapy, in addition, radical chemo-and radio-therapies are an options for the patients who are not fit for surgery (2,3). Non-muscle invasive BCa (10-30%) will unavoidably progress into muscle invasive type (2,4), in line with original muscle invasive BCa, bringing the irreplaceable roles of chemotherapy to BCa management, regardless whether adjuvant or neoadjuvant chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression

Sun

Guan

Liang

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Bladder cancer (BCa) is the most vital urogenital malignant disease worldwide, bringing huge economic and social burden every year. Clinically, BCa is subdivided into superficial type and invasive type according to clinicpathology, accompanied with different strategy of therapy. Number of reports indicate that 10-30% of superficial BCa will inevitable progress into invasive type, manifesting enhanced malignant behavior compared to original invasive type. Regardless of the original being an original invasive type or invasive type that progressed from superficial type of BCa, chemotherapy (including adjuvant or neo-adjuvant chemotherapy) in line with radiotherapy is the final regimen for BCa patients. Previous reports pointed out the high efficiency of cisplatin-containing chemotherapeutic regimen for BCa patients, leading to wide use of this regimen in BCa therapeutics. However, cisplatin-resistance inevitably appear, resulting in the failure of the BCa chemotherapy, the mechanism of which is still unknown. In the present study, parental BCa cell lines T24/J82 were used to obtain stable-cisplatinresistance cell lines T24 R /J82 R , which showed enhanced capacity of malignancy, tumorigenesis and drug resistance, accompanied by elevated expression of EMT markers. The further mechanism investigation suggested that prolonged time of cisplatin-treatment contributed to the activation of the NF-κB signal, resulting in the upregulation of EMT markers, the maintenance of stem cell marker and the elevated expression of ABCB1. Thus, our study provides us a new view of the role of NF-κB signaling in BCa therapeutics.

show abstract

“…Therefore, summarizing all the possible adjuvant therapies under a single definition is not a precise practice. As we know, more effective chemotherapeutic regimens (such the cisplatin-based chemotherapy) cannot be administered to patients with impaired renal function and this difference in chemotherapy (CHT) regimens could act as a confounder [5].…”

Section: We Do Not Have Data About the Presence Of Two Kidneysmentioning

confidence: 99%